This chapter written by different Authors claims and offers a new (yet ancient) view of medicine: the great knowledge of biomedical fields blended with treatment devoted to patient care as a person with a view to developing compliance between physician, healthcare workers and patient. The aim is to try to introduce these matters as part of a university degree course.
Background and objectiveSarcoidosis is a multisystem granulomatous disease with a variable clinical course. While many patients experience spontaneous remission, a substantial proportion develop chronic or relapsing disease requiring prolonged systemic therapy, most commonly corticosteroids. In real-world practice, treatment initiation, tapering strategies, and duration of therapy are heterogeneous, and data on the long-term impact of treatment on comorbidity burden are limited. MethodsWe conducted a retrospective, monocentric observational study including adults with sarcoidosis followed at a tertiary center from January 2010 to November 2025. Demographic, clinical, radiological and therapeutic data were extracted from records. Baseline strategies, corticosteroid exposure, and initiation of immunosuppression were recorded. Associations between treatment exposure and comorbidities were evaluated using regression. ResultsA total of 835 patients were included. At baseline, 81.8% received pharmacologic treatment, most commonly corticosteroids alone. Extrapulmonary involvement was present in 45.4% of patients and was the main determinant of treatment initiation and escalation to immunosuppressive therapy. During follow-up, 664 patients received systemic corticosteroids for a mean cumulative duration of 38.4 ± 64.3 months, and 25.9% required immunosuppressive agents, predominantly methotrexate. Hypertension and bone mineral density impairment were the most frequent comorbidities. Cumulative corticosteroid exposure, but not baseline dose, was independently associated with both hypertension and bone disease. Immunosuppressive therapy was not associated with overall comorbidity burden. ConclusionTreatment decisions were driven primarily by disease phenotype, particularly extrapulmonary involvement. Cumulative corticosteroid exposure was independently associated with hypertension and bone disease. These findings support earlier steroid-sparing strategies and the need for more standardized long-term management.